Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 9:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–47 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TRIESENCE (triamcinolone acetonide injectable suspension) Clear all
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

NCT03097315
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02303184
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
4 mg CLS-TA, Sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

NCT03378076
View directory record Official record
Conditions
Bilateral Knee Osteoarthritis
Interventions
FX006 32 mg, TAcs 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Torrance, California • Rochester, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 12, 2026, 9:28 PM EDT
Terminated Phase 2 Interventional Results available

Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee

NCT02468583
View directory record Official record
Conditions
Post-traumatic Osteoarthritis of the Knee
Interventions
FX006 32 mg, TCA IR 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
20 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 12, 2026, 9:28 PM EDT
Recruiting Phase 2 Interventional

Randomized Placebo Controlled Study of Triamcinolone Acetonide Extended Release Injection for Thumb (CMC) Osteoarthritis

NCT06237153
View directory record Official record
Conditions
Carpometacarpal (CMC) Osteoarthritis
Interventions
Triamcinolone Acetonide extended release suspension
Drug
Lead sponsor
Marie Badalamente
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Phase 4 Interventional

Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance

NCT05058209
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Drug
Lead sponsor
ROC Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 12, 2026, 9:28 PM EDT
Not yet recruiting Phase 4 Interventional

Dose Dependent Steroid Injections

NCT07494136
View directory record Official record
Conditions
Lumbar Radiculopathy, Sciatica, Back Pain With Radiation
Interventions
Triamcinolone 10 Mg/mL Injectable Suspension, Triamcinolone 40 Mg/mL Injectable Suspension, Triamcinolone 80 Mg/mL Injectable Suspension, Dexamethasone 2 MG, Dexamethasone 4mg, Dexamethasone 8 MG
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Not applicable Interventional

Platelet Rich Plasma Versus Corticosteroids in Knee Osteoarthritis Pain

NCT06703970
View directory record Official record
Conditions
Knee Osteoarthritis (OA)
Interventions
Corticosteroid Injection, Platelet Rich Plasma Joint Injection
Drug · Device
Lead sponsor
LifeBridge Health
Other
Eligibility
21 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 12, 2026, 9:28 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip

NCT06977568
View directory record Official record
Conditions
Osteoarthritis of Hip
Interventions
Zilretta, Triamcinolone Acetonide
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
50 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 12, 2026, 9:28 PM EDT
Terminated Phase 4 Interventional Results available

Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint

NCT01045694
View directory record Official record
Conditions
Arthritis Multiple Joint
Interventions
Botulinum Toxin Type A, Steroid - Triamcinolone Acetonide, Lidocaine
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 12, 2026, 9:28 PM EDT
Terminated Phase 1 Interventional

ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis

NCT04831255
View directory record Official record
Conditions
Adhesive Capsulitis, Frozen Shoulder, Adhesive Capsulitis of Shoulder
Interventions
triamcinolone acetonide extended-release injectable suspension
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 12, 2026, 9:28 PM EDT
Terminated Phase 1Phase 2 Interventional

Biological Response to Platelet-rich Plasma and Corticosteroid Injections

NCT05657496
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Triamcinolone Acetonide 40 mg/ml Inj, Susp, Platelet-rich plasma Inj
Drug · Biological
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
40 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

NCT03382262
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Osteoarthritis of the Hip
Interventions
FX006 32 mg, TAcs 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
El Cajon, California • La Mesa, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 12, 2026, 9:28 PM EDT
Terminated Phase 4 Interventional Results available

Trial Comparing Three Single Dose Injections for Knee Osteoarthritis

NCT05492851
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Zilretta, Synvisc-One 48 MG in 6 ML Prefilled Syringe, Monovisc 88 MG Per 4 ML Prefilled Syringe
Drug
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Lewis Center, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

NCT02255032
View directory record Official record
Conditions
Uveitis, Macular Edema, Uveitis, Posterior, Uveitis, Anterior, Panuveitis, Uveitis, Intermediate
Interventions
4 mg CLS-TA, 0.8 mg CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Miami, Florida • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Results available

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

NCT01080131
View directory record Official record
Conditions
Acute Gout
Interventions
Canakinumab 150 mg, Triamcinolone acetonide 40 mg, Placebo to canakinumab, Placebo to triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
96
States / cities
Anniston, Alabama • Birmingham, Alabama • Foley, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

Study of FX006 in Patients With Osteoarthritis of the Knee

NCT01487161
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006, TCA IR
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Tucson, Arizona • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 12, 2026, 9:28 PM EDT
Not listed Phase 3 Interventional

Randomized Placebo-controlled Analysis of Superior Laryngeal Nerve Block for Neurogenic Cough

NCT04468542
View directory record Official record
Conditions
Cough, Nerve Block
Interventions
Superior laryngeal nerve block - Intervention (Bupivacaine and triamcinolone acetonide suspension), Superior laryngeal nerve block - Placebo (saline)
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 12, 2026, 9:28 PM EDT
Terminated Phase 4 Interventional Results available

Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement

NCT02920177
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
platelet-rich plasma injection, Kenalog 10 MG/ML Injectable Suspension
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 12, 2026, 9:28 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

NCT03002974
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Anakinra 100 mg, Triamcinolone Acetonide 40 mg, Placebo to Anakinra 100 mg, Placebo to Triamcinolone Acetonide 40 mg
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 12, 2026, 9:28 PM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552
View directory record Official record
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 12, 2026, 9:28 PM EDT
Recruiting Phase 4 Interventional

Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes

NCT06478186
View directory record Official record
Conditions
Osteoarthritis, Knee, Diabetes Mellitus, Type 2
Interventions
triamcinolone acetonide extended-release injectable suspension; TCA-ER, Triamcinolone Acetonide- Immediate Release;TCA-IR
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 12, 2026, 9:28 PM EDT
Terminated Phase 2 Interventional Results available

Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury

NCT04331002
View directory record Official record
Conditions
Tibial Meniscus Injuries, Tibial Meniscus Tears, Tibial Meniscus, Torn, Anterior Cruciate Ligament Tear
Interventions
Zilretta, Placebo
Drug · Other
Lead sponsor
Austin V Stone
Other
Eligibility
18 Years to 40 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 12, 2026, 9:28 PM EDT